Prostate cancer is the most commonly diagnosed malignancy in men. While tumors initially respond to androgen-deprivation therapy, the standard care for advanced or metastatic disease, tumors eventually recur as castration-resistant prostate cancer. Upregulation of the insulin-like growth factor receptor type 1 (IGF-1R) signaling axis drives growth and progression of prostate cancer by promoting proliferation, survival, and angiogenesis. Ganitumab (formerly AMG 479) is a fully human antibody that inhibits binding of IGF-1 and IGF-2 to IGF-1R. We evaluated the therapeutic value of ganitumab in several pre- Ganitumab was most potent against VCaP xenografts when combined with complete androgendeprivation therapy (castration). Tumor volume was reduced by 72% after 4 weeks of treatment and growth suppression was maintained over 16 weeks of treatment. These data suggest that judicious use of ganitumab particularly in conjunction with androgen-deprivation therapy may be beneficial in the treatment of prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed cancer in men and is the second leading cause of cancer-related deaths in men each year (1). Androgen-deprivation therapy is and has been the gold standard of care for advanced or metastatic prostate cancer for decades. While this treatment strategy initially shows benefit, eventually tumors recur as castration-resistant prostate cancer (CRPC) for which there are limited treatment options with only modest survival benefit.
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The insulin-like growth factor receptor type I (IGF-1R) and native ligands, IGF-1 and IGF-2, are dysregulated in a variety of cancers including prostate cancer (2-5). Signaling through the IGF-1R plays an important role in many cellular processes including: mitogenesis, apoptosis, proliferation, and angiogenesis (Supplementary Figure 1) . The downstream effects of IGF-1R activation include PI3K/AKT and MEK/ERK signaling cascades (6, 7). Elevated levels of serum IGF-1, the most potent activator of IGF-1R, has been correlated with an increased risk of prostate cancer (8, 9). IGF-1 and IGF-1R are increased with progression to castration-resistance in vivo (10). In clinical specimens, IGF-1R expression is elevated in primary prostate cancer versus benign prostatic epithelium (11). Studies with an IGF-1R receptor inhibitor, the antibody cixutumumab (formerly IMC-A12), showed positive results against (19, 20) . In phase I/Ib escalation studies, ganitumab was generally well-tolerated when administered to patients with advanced solid tumors both as a single agent and in combination with either the multi-kinase inhibitor sorafenib, either of the EGFR inhibitors panitumumab or erlotinib, or gemcitabine. These combination therapies as well as ganitumab as a single agent displayed promising anti-tumor effects in patients and resulted in few dose-limiting toxicities, and generally mild adverse 4 events including fatigue, nausea, vomiting or chills (21, 22). To date, ganitumab has shown signs of efficacy against pancreatic cancer and Ewing's sarcoma, yet there has been minimal evaluation of ganitumab for prostate cancer.
In this study, we tested the effect of ganitumab on several human prostate cancer cell lines both in vitro and in vivo. VCaP is an androgen-dependent human prostate cancer cell line that like ~50% of prostate cancers is wild-type for PTEN (a negative regulator for AKT activator PI3K) (23, 24). As observed in human prostate cancer, VCaP cells progress to castration-resistance in vivo (24-26). VCaP also expresses the TMPRSS2:ERG fusion gene, which is seen in ~50% of primary prostate cancer specimens and may promote prostate cancer progression (27). Another androgen-dependent human prostate cancer cell line, LNCaP, does not express active PTEN (28) . CWR-22Rv1 (22Rv1) and CWR-R1 are castration-resistant, PTEN wild-type and express both full length androgen receptor (AR) as well as constitutively active AR splice variants, which lack the ligand binding domain (termed AR∆LBDs) (29, 30) . Utilizing these established models of prostate cancer, we assessed the effectiveness of ganitumab alone and in conjunction with complete androgen-deprivation therapy (castration) as a treatment for androgen-dependent prostate cancer, advanced CRPC, and progression to CRPC. We show that ganitumab inhibits growth of both androgen-dependent and castration-resistant VCaP xenografts.
Ganitumab does not affect growth of aggressive castration-resistant 22Rv1 xenografts. Lastly, we found that ganitumab is highly effective against VCaP xenografts when combined with androgen-deprivation therapy. VCaP cells were tested for prostate and cell line specific characteristics including AR, TMPRSS:ERG fusion, and PSA. VCaP cells were negative for mycoplasma, human T-lymphotropic virus, hepatitis (A, B, and C), and HIV. All cell lines were used within 6 months of resuscitation. VCaP, LNCaP, 22Rv1, and CWR-R1 cells were maintained as previously described (31, 33) . Ganitumab was supplied by Amgen Inc. Recombinant IGF-1 was obtained from Peprotech.
Materials and Methods

Cell
In Vitro AKT Phosphorylation Studies. VCaP and 22Rv1 were plated in medium containing 10% FBS.
At ~70% confluence, medium were replaced with fresh medium supplemented with 5% charcoal-stripped serum and cells cultured for an additional 24 hours. Ganitumab (0-1000 nM) was added 90 minutes prior to treatment with 1nM IGF-1. Cells were harvested in RIPA buffer 30 minutes after IGF-1 administration and immunoblotted.
In Vitro Proliferation Assays. LNCaP, 22Rv1, or CWR-R1 cells were seeded in 24-well plates (BD Falcon) (2x10 4 per well) in RPMI/10% FBS. VCaP cells were seeded in 24-well plates (6x10 4 per well) in DMEM/10% FBS. The following day, cells were washed with PBS, and media supplemented with 2%
FBS and ganitumab was added and incubated for 7 days. Cells were trypsinized (Cellgro), mixed with trypan blue (Gibco), and live cells were counted using a hemocytometer. Data represent at least three independent experiments performed in triplicate.
In Vitro Apoptosis Studies. 6.5x10 5 VCaP, 22Rv1, CWR-R1, or LnCaP were plated in the appropriate medium containing 10% FBS in 60mm plates. The following day, cell monolayers were washed with PBS, and medium supplemented with 2%FBS containing 500nM ganitumab or vehicle was added. Plates were incubated for 3 days, harvested in RIPA buffer and immunoblotted. Data represent at least two independent experiments.
Western Blots. Western blots were performed as previously described (31, 33) . Antibodies against phospho-AKT (S73), total AKT, IGF-1R, and cleaved PARP were obtained from Cell Signaling. INSR, 6 actin (Santa Cruz), HRP-conjugated secondary antibodies were obtained from (Santa Cruz).
Densitometry was performed using Adobe Photoshop CS3.
Xenograft studies. Studies involving animals were conducted in a manner approved by the University of Miami Animal Care and Use Committee. VCaP xenografts were established as previously described (31, 33) . 22Rv1 cells (2x10 6 ) were injected subcutaneously into both hind flanks of castrated nude mice (Harlan) with Matrigel (BD Biosciences). Tumor volumes were assessed as previously described (33) .
Mice were euthanized when tumors reached a maximal volume of 1000mm 3 or 10 weeks post-treatment for androgen-replete VCaP xenografts; 1000 mm 3 or 17 weeks post-treatment for castration-resistant VCaP xenografts; and 1000 mm 3 or 7 weeks post-treatment for castration-resistant 22Rv1 xenografts;
upon which tumors were excised, and flash frozen. Levels of circulating PSA were quantified from serum samples by an enzyme-linked immunosorbent assay (Biocheck Inc.). Levels of IGF-1R, INSR, phospho-AKT and total AKT were measured using either MSD multiplex assays (Meso Scale Discovery)
as previously described (5, 18) or densitometry as described above. Ganitumab (Amgen) and control anti-streptavidin IgG1 antibody (Amgen) were diluted in sterile PBS and administered via intraperitoneal injections at a dosage of 300µg twice weekly as specified. 8 had no effect on levels of AR (Supplementary Figure 2a) . These data show that ganitumab slows the growth of this androgen-dependent prostate cancer model.
Results
Ganitumab inhibits IGF
Effect of ganitumab treatment on castration-resistant prostate cancer in vivo
To test whether ganitumab may be effective for CRPC, we utilized two xenograft models. VCaP xenografts are initially androgen-dependent, but recur as castration-resistant xenografts after murine castration (26, 33). VCaP cells were injected into the flanks of intact SCID mice and mice were castrated when average tumor volumes reached 260~320 mm 3 . Castrated mice with tumors averaging 538 mm 3 were randomized into 2 groups and treatment with ganitumab or continued control antibody was initiated.
This experimental design allowed evaluation of ganitumab effectiveness for tumors that had recently progressed to castration-resistance.
Ganitumab halted tumor growth for the remainder of the experiment (11.5 weeks) whereas the tumors of the control-treated mice continued to grow rapidly ( Figure 3a) . The ganitumab-treated mice Table 1a ). Protein levels of IGF-1R
were significantly decreased in ganitumab-treated mice compared to control treated mice (Figure 4b-c) .
INSR, AR, and AR∆LBD levels were not significantly changed after treatment with ganitumab ( Figure   4b ,d) (Supplementary Figure 2c) .
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Ganitumab combined with androgen-deprivation is a highly effective treatment regimen
The standard of care for advanced or metastatic prostate cancer is androgen-deprivation therapy.
Since ganitumab showed inhibitory effects on both androgen-dependent and castration-resistant VCaP prostate cancer xenografts, we tested whether combining ganitumab with androgen-deprivation therapy Figure 4) . These data show that combination of ganitumab and androgen-deprivation substantially decreased tumor growth and delayed progression to castration resistance.
Reversibility and durability of treatment with ganitumab combined with androgen-deprivation therapy
We evaluated the durability of combining androgen-deprivation therapy with ganitumab treatment by examining long-term ganitumab treatment. Reversibility of ganitumab treatment was also assessed. VCaP xenografts were established and mice castrated when tumors reached an average volume of 260-320 mm 3 . Treatment with ganitumab commenced one week after castration. Five weeks after castration, mice were randomized into two groups. One group remained on ganitumab (to evaluate durability of response) and ganitumab was discontinued in the other group (to evaluate reversibility of response). In the ganitumab discontinued cohort, all tumors (n=4) recurred within 11 weeks (Figure 6a ).
Two of 5 tumors recurred in the long-term ganitumab treatment arm (Figure 6b ). Thus, while combination therapy with androgen-deprivation and ganitumab is highly effective, tumors recur after ganitumab cessation and some tumors recur during long-term ganitumab treatment.
Discussion
A major problem in the care of advanced prostate cancer is the lack of a durable response to androgen-deprivation therapy. Ganitumab is a fully human antibody that targets and inhibits IGF-1R by blocking ligand binding that has shown promising efficacy in the treatment of pancreatic cancer and PTEN has been suspected to play a role in the efficacy of IGF-1R inhibitors as PTEN is a negative regulator of the PI3K/AKT pathway, which is major downstream effector of IGF-1R (7, 23).
PTEN deficiencies lead to highly active, hyperphosphorylated AKT in the absence of exogenous signaling (35) . PTEN is not expressed or is inactive in a significant number of prostate cancers (28, 36) .
The prostate cancer cell model LAPC-4, which harbors a wild-type PTEN, was recently shown to be insensitive to ganitumab in vitro (37) . Harboring wild-type PTEN does not appear to be sufficient for sensitivity to ganitumab as also evidenced by a lack of response of 22Rv1 xenografts in castrated mice. 
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be clinically beneficial prior to androgen-deprivation therapy in the treatment of prostate cancer, although a role for AR is currently unclear.
Castration-resistant VCaP xenograft growth was also inhibited by ganitumab treatment.
Ganitumab prevented significant increases in tumor volume in these castration-resistant xenografts throughout the duration of treatment (11.5 weeks). Since there are limited treatment options for established castration resistant tumors, blocking IGF-1R with ganitumab may be an effective strategy in this setting.
Ganitumab treatment did not inhibit castration-resistant growth of 22Rv1 xenografts (Fig. 2) or growth of 22Rv1 tumors in intact (androgen-replete) mice (37) . Thus, 22Rv1 cells exhibit de novo resistance to ganitumab in vivo. In contrast, VCaP xenografts were strikingly growth inhibited in the presence or absence of androgen in vivo. These cell lines are distinct. 22Rv1 are an aggressive CRPC line developed by serial passage of androgen-dependent CWR22 xenografts in castrated mice (29) . 22Rv1 proliferate in the absence of serum (31) whereas VCaP cells rely on serum for growth and are initially androgen-dependent taking several weeks to achieve castration-resistance in vivo (33) . VCaP express higher levels of IGF-1R compared to 22Rv1. VCaP and 22Rv1 also express different levels of AR (wild type in VCaP, mutated in 22Rv1) and AR∆LBDs. VCaP express higher levels of ERG than 22Rv1 and express the TMPRSS2:ERG fusion protein, seen in ~50% of prostate cancer specimens, whereas 22Rv1 do not contain the TMPRSS2:ERG fusion (39, 40) . These data suggest that 22Rv1 and VCaP rely on different signals for survival and proliferation, which may underlie differential response to ganitumab.
Thus, more mechanism-based research is needed in order to stratify patients based on molecular and genetic features of their prostate tumors.
In our preclinical study, ganitumab was most effective when combined with a more complete androgen-deprivation therapy. To date, no clinical trials have combined complete androgen-deprivation therapy (using abiraterone or the AR antagonist enzalutamide) with IGF-1R inhibition. Based on clinical trials, ganitumab is also suitable and well-tolerated alone and in combination with a variety of chemotherapeutic agents including the multi-kinase inhibitor sorafenib, EGF-R inhibitors panitumumab 13 and erlotinib, or the nucleoside analogue gemcitabine (22). In fact, the only prostate cancer patient who participated in this study showed a partial response (~60% maximum change from baseline tumor size) in response to ganitumab plus gemcitabine.
PSA is a clinical biomarker used extensively to evaluate incidence and recurrence of prostate cancer. Recent studies have shown wide variability in PSA levels and suggest that PSA may not be suitable as a surrogate end point in clinical trials involving non-cytotoxic drugs such as ganitumab (41) .
We found that PSA levels were increased with no parallel increase in tumor volume, AR expression, or AR∆LBD expression in ganitumab-treated mice harboring castration-resistant VCaP xenografts. Mice treated with both androgen-deprivation therapy and long-term ganitumab showed increased AR and AR3 mRNA levels compared to control-treated mice. However, our studies were only able to assess transcript levels in this setting, which are not necessarily indicative of protein expression or function (transcriptional activity). The molecular basis for the discrepancy between PSA levels and tumor volume in our preclinical models is not known but suggests that serum PSA may not be an ideal biomarker for clinical evaluation of recurrence during treatment with ganitumab.
Some VCaP xenografts acquired resistance to the combined treatment of ganitumab and androgen-deprivation (castration). Development of resistance to therapy is a major and common problem in cancer care. In models of Ewing's sarcoma, upregulation of signaling by the closely related INSR is an important mechanism of resistance to ganitumab (5). However, we saw no increase in levels of INSR in any xenograft experiments or increased phospho-AKT levels when ganitumab was combined with androgen deprivation, thus it is unlikely that upregulation of INSR is a mechanism of resistance to ganitumab in either VCaP or 22Rv1 prostate cancer cell models. Since mTOR can potentiate compensatory pathways, co-administering ganitumab with an mTOR inhibitor may be effective in combating drug resistance. Further investigation into the mechanism of acquired resistance to ganitumab in prostate cancer is needed.
Our data suggest that ganitumab may be beneficial in the treatment of both androgen-dependent and some forms of CRPC. Importantly, ganitumab plus complete androgen-deprivation therapy was 
